Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Delta9-tetrahydrocannabinol.

Buchweitz JP, Karmaus PW, Williams KJ, Harkema JR, Kaminski NE.

J Leukoc Biol. 2008 Mar;83(3):785-96. Epub 2007 Dec 11.

PMID:
18073275
2.

Targeted deletion of cannabinoid receptors CB1 and CB2 produced enhanced inflammatory responses to influenza A/PR/8/34 in the absence and presence of Δ9 -tetrahydrocannabinol.

Buchweitz JP, Karmaus PWF, Williams KJ, Harkema JR, Kaminski NE.

J Leukoc Biol. 2008 Mar;83(3):785-796. doi: 10.1189/jlb.0907618.

PMID:
29350853
3.

Modulation of airway responses to influenza A/PR/8/34 by Delta9-tetrahydrocannabinol in C57BL/6 mice.

Buchweitz JP, Karmaus PW, Harkema JR, Williams KJ, Kaminski NE.

J Pharmacol Exp Ther. 2007 Nov;323(2):675-83. Epub 2007 Aug 28.

4.

Role of cannabinoid receptors in Delta-9-tetrahydrocannabinol suppression of IL-12p40 in mouse bone marrow-derived dendritic cells infected with Legionella pneumophila.

Lu T, Newton C, Perkins I, Friedman H, Klein TW.

Eur J Pharmacol. 2006 Feb 17;532(1-2):170-7. Epub 2006 Jan 27.

PMID:
16443217
5.

Beneficial effects of cannabinoids (CB) in a murine model of allergen-induced airway inflammation: role of CB1/CB2 receptors.

Braun A, Engel T, Aguilar-Pimentel JA, Zimmer A, Jakob T, Behrendt H, Mempel M.

Immunobiology. 2011 Apr;216(4):466-76. doi: 10.1016/j.imbio.2010.09.004. Epub 2010 Sep 18.

PMID:
21056512
6.

Δ9-tetrahydrocannabinol impairs the inflammatory response to influenza infection: role of antigen-presenting cells and the cannabinoid receptors 1 and 2.

Karmaus PW, Chen W, Crawford R, Kaplan BL, Kaminski NE.

Toxicol Sci. 2013 Feb;131(2):419-33. doi: 10.1093/toxsci/kfs315. Epub 2012 Nov 14.

7.

Role of cannabinoid receptors in inhibiting macrophage costimulatory activity.

Chuchawankul S, Shima M, Buckley NE, Hartmann CB, McCoy KL.

Int Immunopharmacol. 2004 Feb;4(2):265-78.

PMID:
14996418
8.

Cannabinoid-mediated elevation of intracellular calcium: a structure-activity relationship.

Rao GK, Kaminski NE.

J Pharmacol Exp Ther. 2006 May;317(2):820-9. Epub 2006 Jan 25.

9.

Cannabinoid receptors CB1 and CB2: a characterization of expression and adenylate cyclase modulation within the immune system.

Schatz AR, Lee M, Condie RB, Pulaski JT, Kaminski NE.

Toxicol Appl Pharmacol. 1997 Feb;142(2):278-87.

PMID:
9070350
10.

Role of cannabinoid receptors in alcoholic hepatic injury: steatosis and fibrogenesis are increased in CB2 receptor-deficient mice and decreased in CB1 receptor knockouts.

Trebicka J, Racz I, Siegmund SV, Cara E, Granzow M, Schierwagen R, Klein S, Wojtalla A, Hennenberg M, Huss S, Fischer HP, Heller J, Zimmer A, Sauerbruch T.

Liver Int. 2011 Jul;31(6):860-70. doi: 10.1111/j.1478-3231.2011.02496.x. Epub 2011 Mar 8.

PMID:
21645218
11.

Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation via cannabinoid receptor-independent signaling.

Takeda S, Yamaori S, Motoya E, Matsunaga T, Kimura T, Yamamoto I, Watanabe K.

Toxicology. 2008 Mar 12;245(1-2):141-6. doi: 10.1016/j.tox.2007.12.019. Epub 2007 Dec 28.

PMID:
18249480
12.

Δ9-tetrahydrocannabinol suppresses cytotoxic T lymphocyte function independent of CB1 and CB 2, disrupting early activation events.

Karmaus PW, Chen W, Kaplan BL, Kaminski NE.

J Neuroimmune Pharmacol. 2012 Dec;7(4):843-55. doi: 10.1007/s11481-011-9293-4. Epub 2011 Jul 26.

13.

Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.

Zhu LX, Sharma S, Stolina M, Gardner B, Roth MD, Tashkin DP, Dubinett SM.

J Immunol. 2000 Jul 1;165(1):373-80.

14.
15.

Delta9-tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation.

Caffarel MM, Sarrió D, Palacios J, Guzmán M, Sánchez C.

Cancer Res. 2006 Jul 1;66(13):6615-21.

16.

Effects of targeted deletion of cannabinoid receptors CB1 and CB2 on immune competence and sensitivity to immune modulation by Delta9-tetrahydrocannabinol.

Springs AE, Karmaus PW, Crawford RB, Kaplan BL, Kaminski NE.

J Leukoc Biol. 2008 Dec;84(6):1574-84. doi: 10.1189/jlb.0508282. Epub 2008 Sep 12.

17.

Mice lacking cannabinoid CB1-, CB2-receptors or both receptors show increased susceptibility to trinitrobenzene sulfonic acid (TNBS)-induced colitis.

Engel MA, Kellermann CA, Burnat G, Hahn EG, Rau T, Konturek PC.

J Physiol Pharmacol. 2010 Feb;61(1):89-97.

18.

Anti-inflammatory activity of topical THC in DNFB-mediated mouse allergic contact dermatitis independent of CB1 and CB2 receptors.

Gaffal E, Cron M, Glodde N, Tüting T.

Allergy. 2013 Aug;68(8):994-1000. doi: 10.1111/all.12183. Epub 2013 Jul 29.

PMID:
23889474
19.

CB(2) cannabinoid receptor antagonist SR144528 decreases mu-opioid receptor expression and activation in mouse brainstem: role of CB(2) receptor in pain.

Páldy E, Bereczki E, Sántha M, Wenger T, Borsodi A, Zimmer A, Benyhe S.

Neurochem Int. 2008 Dec;53(6-8):309-16. doi: 10.1016/j.neuint.2008.08.005. Epub 2008 Aug 29.

PMID:
18804501

Supplemental Content

Support Center